New trend of lung cancer tumor immunity: Can K drug receiver o drug regain growth?

On May 29, 2020, as of 1c
, as the ASCO conference line was opened, and nine heavy "late-breaking abstracts" were updated, including 1Avelumab pee road skin cancer maintenance JAVELIN Bladder 100; 2Coreida MSI-H/dMMR first-line indications of colorectal cancer KEYNOTE-177;3Ohitinib early non-small cell lung cancer assistadaURA; 4Avelumab has been updated with the rare gynaecological cancer TROPHIMMUNInterested readers can access the end-of-article linkin recent years, in the field of lung cancer, targeted chemotherapy and tumor immunotherapy have profoundly changed the treatment options for lung cancer patients, and increasingly accurate targeted chemotherapy programs and increasingly innovative tumor immunotherapy have gradually expanded the beneficiariesAt the 2020 ASCO conference, there were a number of key updates to non-small cell lung cancer and small cell lung cancer, including the following:1EGFR exon 20 insertion mutation non-small cell lung cancer, Oichtinib (#9513), double anti-amivantamab (#9512) data update, EGFR exon 20 insertion of this segment of patients will usher in a breakthrough, Takeda mobocertinib and Johnson and Johnson double antiamivantamab will be two drugs of interest;2Ohitinib (#LBA5) updated the adaURA data for postoperative assisted treatment of non-small cell lung cancer patients with IB-IIIA mutation, and the risk of disease progression was reduced by 79% in patients with IB-IIIA, and it is expected that Ochitini will cover advanced metastatic non-small first- and second-line, early-cell lung cancer-assisted therapyThe smooth expansion of early-assisted indications will add strong growth momentum to Ochtini's future market;3trastuzumab deruxtecan (#9504) updates her2 mutant non-small cell lung cancer data, orR 61.9% of 42 non-small cell lung cancer patients, and excellent tumor response, according to which the FDA awarded its third breakthrough therapy;1 Tiragolumab's detailed subgroup data updates (#9503), tiragolumab combined with atlizumab can further contribute to the clinical benefits of PD-L1 high expression patients; 2 Odivor updated non-small cell lung cancer first line CheckMate 9LA (#9501), Navuli Ummasinatagain , ipitumite, combined 2 cycle chemotherapy, clinical benefits are clear Recently, Oedivo successfully expanded the first-line indications of non-small cell lung cancer with CheckMate 227,9LA; 3 Coreyda updated the first-line large-stage small cell lung cancer KEYNOTE-604 (#9001), but Reda was able to significantly reduce the risk of disease progression, but Coreyda vs The placebo failed to significantly improve patient survival; 4 Infifan updates extensive small cell lung cancer WITHIEAN (#9002), Durvalumab and tremelimumab,platinum-etoposide group total survival benefits are no different from individual chemotherapy, as one of CTLA4 monotophobics, tremelimumab due to low Treg removal ability, the market value has basically disappeared due to low Treg removal ability; this article will focus on the 2020 astherapy for cooma Coreda with KEYNOTE-024, 42, 189, 407, Canrida or combined chemotherapy has successfully expanded the scale, non-squamous non-small cell lung cancer first-line indications, in the non-small cell lung cancer has firmly grasped the unshakable advantage! In 2019, Corey Ida's annual sales of $11 billion, non-small cell lung cancer indications contribute more than half! lung cancer first-line indications: KEYNOTE-604 official disadvantage
Coreda has won the first-line victory of non-small cell lung cancer, at present, in small cell lung cancer, can Rida approved the 3 line of small cell lung cancer, first-line indications, Coreida has not yet built Lung cancer attack slightly, KEYNOTE-604 can be called the battle of Thereida! KEYNOTE-604: mPFS 4.8 vs 4.3, HR 0.73, significantly improved PFS -604: mOS 10.8 vs 9.7, HR 0.80, not statistically significant
the clinical results of KEYNOTE-604 are still surprising, in patients with a wide range of small cell lung cancer, canreda combination of optoside and platinum chemotherapy, can significantly improve the survival of patients without progression, but the overall risk of progression The induction and maintenance periods, IMpower133 vs CASPIAN vs KEYNOTE-604 design is similar, wherein the KEYNOTE-604 maintenance period is also the Coreda joint endopoine-platinum chemotherapy, 4 cycles In small cell lung cancer indications, Corey "turned over" IMpower133 vs CASPIAN vs KEYNOTE-604
IMpower133 vs CASPIAN vs KEYNOTE-604: Corey Ida did not perform OS advantage
2020, Baxter's first-quarter results disclosed Odivor's global sales of $1.766 billion, down $100 million from the fourth quarter of 2019 May 15, 2020, May 26, Odivor has been approved for non-small cell lung cancer first-line indications with CheckMate 227 and 9LA, which is a key expansion of Odivor's lung cancer indications the author here simply compares several key programs of advanced non-small cell lung cancer first-line indications: PD-(L)1 combined chemotherapy, PD-(L) 1 - bevalpzumab combined with chemotherapy, PD-(L)1 combined ipitizumab-chemotherapy, these programs have been approved for non-small cell lung cancer first-line indications, treatment costs and checkmate-9LA chemotherapy and Ipituzumab are worth discussing the clinical benefits of the two CITYSCAPE: PD-L1 High Expression Patient ORR 66% vs 24% CITYSCAPE: PD-L1 high expression patients, mPFS not reached vs 4.1Nov, HR 0.30 CITYSCAPE: Atalizumab single anti-drug performance is not satisfactory
CITYSCAPE clinical data show that tiragolumab combined with atilinal seinadesacantadcantadaros can significantly improve clinical benefits of PD-L1 high expression patients, CITYSCAPE vs IMpower110 comparison: 1 Atlizhu singic control, CITYSCAPE in TPS greater than 50% sub-group progression survival period of 4.11 months, IMpower110 in TC3 or IC3 , TC , OR IC , 10% PD-L1 , total survival of 20.2 months, CITYSCAPE's progression-free survival is a bit low; CITYSCAPE and IMpower110 patients baseline is different, PD-L1 expression measurement test method is also different, the former, 22C3 ICH, the latter SP142, although can not be directly compared, but CITYSCAPE's progression-free survival is indeed low; Tiragolumab's joint atlizumab only increased clinical benefits in PD-L1 high-expression patients, which is still instructive for the clinical development of other TIGIT monotorsis Source: 1.